Videos

Daniel Cancilla, MD, discusses a study performed at the Cleveland Clinic where a new protocol for plerixafor usage for stem cell transplantation was implemented with the goal of cost savings.

Peterson discusses the investigation of ruxolitinib in the second line for patients with acute graft-vs-host disease following allogeneic hematopoietic stem cell transplant.

Panelists examine multidisciplinary teams and coordination of care for patients with non-small cell lung cancer, including when to involve surgeons, oncologists, and radiation oncologists.

Medical professionals discuss the role of neoadjuvant/perioperative immunotherapy in subgroups of patients with NSCLC with actionable genomic aberrations, including a brief look at the ALINA and ADUARA trials.

Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, discuss the role of molecular profiling to guide precision treatment decisions in non-small cell lung cancer, including the impact of PD-L1 status on neoadjuvant and perioperative approaches.

Hedyeh Ebrahimi, MD, MPH, discusses a study that found adding the live bacterial product CBM588 to standard immunotherapy potentially impacted patients' responses in renal cell carcinoma.

Abdullah M. Khan, MBBS, discusses the recent updates to data on the use of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Betty K. Hamilton, MD, discusses findings from a study comparing gilteritinib vs placebo post-allogeneic hematopoietic cell transplantation for the treatment of patients with FLT3-ITD-positive acute myeloid leukemia.

Michael Scordo, MD, discusses the implications of a new approach to dosing antithymocyte globulin in patients undergoing an allogeneic hematopoietic stem cell transplant.

Following a comprehensive review of CAPItello-291, Rohit Gosain, MD, and Rahul Gosain, MD, provide closing thoughts on key takeaways.

Focusing on the safety profile, the Oncology Brothers and Hope Rugo, MD, review safety data from CAPItello-291 and discuss adverse event management practices for patients with breast cancer.

Hope Rugo, MD, reviews key data from CAPItello-291 on capivasertib in patients with HR+ breast cancer, highlighting progression-free survival and overall survival.

Medical oncologists provide insights on biomarker testing and the prevalence of AKT1, PIK3CA, and PTEN mutations in breast cancer.

Hope Rugo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the rationale and study design for CAPItello-291 in HR+ advanced breast cancer.

Adam Binder, MD, discusses what he found to be notable from the results of the phase 3 BOSTON trial that looked at the efficacy of selinexor, bortezomib, and dexamethasone triplet therapy for patients with relapsed/refractory multiple myeloma.

Matthew Matasar, MD, highlights the use of mosunetuzumab-axgb for the treatment of patients with follicular lymphoma.

Ibrahim N. Muhsen, MD, discusses the findings and key takeaways from his presentation given at the 2024 Tandem Meeting.

Dr. Hammers discusses recent efficacy and safety data updates from CHECKMATE-214, KEYNOTE-426, and CHECKMATE-9ER trials.

Dr. Hammers summarizes key efficacy findings from the CLEAR study of pembrolizumab + lenvatinib vs sunitinib.

Matthew Matasar, MD, discusses the phase 3 SYMPATICO study of ibrutinib given in combination with venetoclax vs ibrutinib and placebo for the treatment of patients with relapsed/refractory mantle cell lymphoma.

Bruno R. Bastos, MD, discusses the future following a study assessing the changes among patients with renal cell carcinoma who were treated with nivolumab and TPST-1120.

Analyze the appropriate washout period when switching between KRAS inhibitors.

Review evidence on sequencing of KRAS inhibitors after progression on the initial treatment.

Habte Yimer, MD, provides an overview of the ALPINE trial of zanubrutinib vs ibrutinib among patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Lori J. Wirth, MD, provides an overview on the latest advancements in diagnosis of thyroid cancer.

Michiel S. Van der Heijden, MD, PhD, discusses the methods, design, and findings of the phase 3 CheckMate 901 trial of concurrent frontline nivolumab and chemotherapy followed by nivolumab maintenance therapy in urothelial carcinoma.

Pedro Barata, MD, MSc, FACP, discusses tackling unmet needs in oncology at the NRG Oncology Semiannual Meeting taking place February 15-17, 2024.

Dr. Hammers provides a perspective on the appropriateness of initial pembrolizumab + lenvatinib therapy based on guidelines.

Pedro Barata, MD, MSc, FACP, discusses the goals of the NRG Oncology Semiannual Meeting taking place February 15-17, 2024.

Dr. Hammers discusses initial impressions of the case presentation, comparing it to typical advanced RCC, and reviewing risk factors.